These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16212005)

  • 21. [Alcoholic and non-alcoholic fatty liver hepatitis. When is abstaining from alcohol enough, when do steroids help?].
    Berghaus TM; Beuers U
    MMW Fortschr Med; 2001 Jul; 143(26-27):28-32. PubMed ID: 11481912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Alcoholic and non-alcoholic steatohepatitis: who is affected and what can we do for them?].
    Gallego-Durán R; Ampuero J; Funuyet J; Romero-Gómez M
    Gastroenterol Hepatol; 2013 Nov; 36(9):587-96. PubMed ID: 24011648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Nonalcoholic steatohepatitis (NASH): therapeutic approaches].
    Buscher HP
    Dtsch Med Wochenschr; 2004 Sep; 129 Suppl 2():S60-2. PubMed ID: 15368170
    [No Abstract]   [Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment.
    Bugianesi E; Marzocchi R; Villanova N; Marchesini G
    Best Pract Res Clin Gastroenterol; 2004 Dec; 18(6):1105-16. PubMed ID: 15561641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Nonalcoholic steatohepatitis--current treatment options].
    Gutkowski K; Gutkowska D; Partyka M
    Przegl Lek; 2006; 63(2):91-4. PubMed ID: 16967716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease.
    Moschen AR; Tilg H
    Curr Opin Clin Nutr Metab Care; 2008 Sep; 11(5):620-5. PubMed ID: 18685459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome.
    Tarantino G; Saldalamacchia G; Conca P; Arena A
    J Gastroenterol Hepatol; 2007 Mar; 22(3):293-303. PubMed ID: 17295757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic fatty liver disease: the potential role of nutritional management.
    Leclercq IA; Horsmans Y
    Curr Opin Clin Nutr Metab Care; 2008 Nov; 11(6):766-73. PubMed ID: 18827582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: diagnosis and treatment of non-alcoholic fatty liver disease.
    Oh MK; Winn J; Poordad F
    Aliment Pharmacol Ther; 2008 Sep; 28(5):503-22. PubMed ID: 18532991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical aspects of non-alcoholic fatty liver disease.
    Björnsson E
    Minerva Gastroenterol Dietol; 2008 Mar; 54(1):7-18. PubMed ID: 18299664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Non-alcoholic fatty liver disease in children: a new complication of obesity].
    Bocca G; Stolk RP; Scheenstra R; Sauer PJ
    Ned Tijdschr Geneeskd; 2008 Nov; 152(45):2443-7. PubMed ID: 19051794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Fatty hepatosis. Non-alcoholic steatohepatitis (evolution of the knowledge about clinico-morphological features, prognosis, treatment)].
    Podymova SD
    Ter Arkh; 2006; 78(4):32-8. PubMed ID: 16821419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease.
    Bayard M; Holt J; Boroughs E
    Am Fam Physician; 2006 Jun; 73(11):1961-8. PubMed ID: 16770927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-alcoholic fatty liver disease pathogenesis: the present and the future.
    Petta S; Muratore C; Craxì A
    Dig Liver Dis; 2009 Sep; 41(9):615-25. PubMed ID: 19223251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis.
    Miele L; Forgione A; Hernandez AP; Gabrieli ML; Vero V; Di Rocco P; Greco AV; Gasbarrini G; Gasbarrini A; Grieco A
    Eur Rev Med Pharmacol Sci; 2005; 9(5):273-7. PubMed ID: 16231589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
    Park SH
    Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-alcoholic steatohepatitis in children.
    Roberts EA
    Clin Liver Dis; 2007 Feb; 11(1):155-72, x. PubMed ID: 17544977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in nonalcholic fatty liver disease.
    Greenfield V; Cheung O; Sanyal AJ
    Curr Opin Gastroenterol; 2008 May; 24(3):320-7. PubMed ID: 18408460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic fatty liver disease: a review.
    Poordad FF
    Expert Opin Emerg Drugs; 2005 Aug; 10(3):661-70. PubMed ID: 16083334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.